Patents by Inventor Shuqun Lin

Shuqun Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20220356180
    Abstract: Compounds having the following formula I. or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: April 29, 2021
    Publication date: November 10, 2022
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang, Qingjie Liu
  • AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20200071315
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: November 18, 2019
    Publication date: March 5, 2020
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Yanlei, Qingjie Liu
  • Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
    Patent number: 10526321
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: January 7, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stephen T. Wrobleski, Shuqun Lin
  • Tricyclic heterocyclic compounds useful as inhibitors of TNF
    Patent number: 10308652
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: —(CR3R3)2-5-, —(CR3R3)x-Y—(CR3R3)y-, —Y—(CR3R3)2-3-Y—, —CR3R3-Y—(CR3R3)2-Y—, —Y—(CR3R3)2-Y—CR3R3-; and Y, R1, R2, R3, R5, R6, R8, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: June 4, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stephen T. Wrobleski, Gregory D. Brown, Shuqun Lin, Jingwu Duan, Zhonghui Lu, Murali T. G. Dhar, Hai-Yun Xiao, Andrew J. Tebben
  • AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20180265504
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: May 15, 2018
    Publication date: September 20, 2018
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang, Qingjie Liu
  • Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
    Patent number: 10000480
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: June 19, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang, Qingjie Liu
  • TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF
    Publication number: 20180111937
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: —(CR3R3)2-5-, —(CR3R3)x-Y—(CR3R3)y-, —Y—(CR3R3)2-3-Y—, —CR3R3-Y—(CR3R3)2-Y—, —Y—(CR3R3)2-Y—CR3R3-; and Y, R1, R2, R3, R5, R6, R8, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Application
    Filed: March 17, 2016
    Publication date: April 26, 2018
    Inventors: Stephen T. WROBLESKI, Gregory D. BROWN, Shuqun LIN, Jingwu DUAN, Zhonghui LU, Murali T.G. DHAR, Hai-Yun XIAO, Andrew J. TEBBEN
  • AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20170022192
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: October 10, 2016
    Publication date: January 26, 2017
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang, Qingjie Liu
  • Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: 9505748
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: November 29, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Shuqun Lin, Steven H. Spergel, Yanlei Zhang
  • Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: 9315494
    Abstract: Compounds having the following formula (I): or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: April 19, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, Shuqun Lin, David S. Weinstein, Stephen T. Wrobleski, Yanlei Zhang, John S. Tokarski, Michael E. Mertzman
  • Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
    Patent number: 9221826
    Abstract: Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: December 29, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stephen T. Wrobleski, Jagabandhu Das, Lidia M. Doweyko, Junqing Guo, John Hynes, Bin Jiang, James Kempson, Shuqun Lin, Steven H. Spergel, John S. Tokarski, Hong Wu, Bingwei Vera Yang
  • ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20150307483
    Abstract: Compounds having the following formula (I): or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: November 7, 2013
    Publication date: October 29, 2015
    Inventors: Ryan M. Moslin, Shuqun Lin, David S. Weinstein, Stephen T. Wrobleski, Yanlei Zhang, John S. Tokarski, Michael E. Mertzman
  • AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20150299183
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: November 7, 2013
    Publication date: October 22, 2015
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S, Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang
  • Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
    Patent number: 8987268
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: March 24, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stephen T. Wrobleski, Jagabandhu Das, Jingwu Duan, Junqing Guo, John Hynes, Bin Jiang, James Kempson, Shuqun Lin, Zhonghui Lu, William J. Pitts, Steven H. Spergel, Hong Wu, Bingwei Vera Yang
  • Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
    Patent number: 8921368
    Abstract: Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: December 30, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stephen T. Wrobleski, Gregory D. Brown, Lidia M. Doweyko, Jingwu Duan, Junqing Guo, John Hynes, Bin Jiang, James Kempson, Shuqun Lin, Zhonghui Lu, Steven H. Spergel, John S. Tokarski, Hong Wu, Bingwei Vera Yang
  • PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
    Publication number: 20140011800
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
    Type: Application
    Filed: March 16, 2012
    Publication date: January 9, 2014
    Inventors: Stephen T. Wrobleski, Jagabandhu Das, JIngwu Duan, Junqing Guo, John Hynes, Bin Jiang, James Kempson, Shuqun Lin, Zhonghui Lu, William J. Pitts, Steven H. Spergel, Hong Hu, Bingwei Vera Yang
  • PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
    Publication number: 20140011795
    Abstract: Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
    Type: Application
    Filed: March 16, 2012
    Publication date: January 9, 2014
    Inventors: Stephen T. Wrobleski, Gregory D. Brown, Lidia M. Doweyko, Jingwu Duan, Junqing Guo, John Hynes, Bin Jiang, James Kempson, Shuqun Lin, Zhonghui Lu, Steven H. Spergel, John S. Tokarski, Hong Wu, Bingwei Vera Yang
  • PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
    Publication number: 20140005146
    Abstract: Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
    Type: Application
    Filed: March 16, 2012
    Publication date: January 2, 2014
    Inventors: Stephen T. Wrobleski, Jagabandhu Das, Lidia M. Doweyko, Junqing Guo, John Hynes, Bin Jiang, James Kempson, Shuqun Lin, Steven H. Spergel, John S. Tokarski, Hong Wu, Bingwei Vera Yang
  • Heterocyclic amide compounds useful as kinase inhibitors
    Patent number: 8404689
    Abstract: A compound of Formula I and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions associated with the activity of p38 kinase.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: March 26, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stephen T. Wrobleski, Jagabandhu Das, T. G. Murali Dhar, Alaric J. Dyckman, John Hynes, Katerina Leftheris, James Lin, Shuqun Lin
  • Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: RE47929
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: April 7, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Shuqun Lin, Steven H. Spergel, Yanlei Zhang